Many PARP1 inhibitors (oxaliplatin, PJ-34, 3-aminobenzamide, olaparib) have been studied in stroke, Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), but have not been clinically evaluated [61]. Here, PARP1 is linked to Stroke.